Lipid profile of infected patients treated with highly active antiretroviral therapy in Cameroon

Journal of Medical Sciences

Volumn 7, Issue 4, 2007, Pages 670-673

  Ngondi, Judith Laure ^a,c   Etame, S H L ^a,b   Fonkoua, M ^a   Yangoua, H ^a   Oben, J ^a  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b National Institute of Medicinal Plant and Medical Research   (Cameroon)

^c Ngondi Rebecca Rachelle Foundation   (Cameroon)

Author keywords

Dyslipidemia; Highly active antiretroviral therapy; HIV infection; Hypertriglyceridemia

Indexed keywords

CHOLESTEROL; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INDINAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAMEROON; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34250834992     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2007.670.673     Document Type: Article

References (18)

1. Allain, C.C., L.S. Poon, C.G. Chan, W. Richmond and P.C. Fu, 1974. Quantitative determination of serum cholesterol by the use of enzymes. Clin. Chem., 20: 470-475.
2. Behrens, G., H. Shmidt, D. Meyer, M. Stoll and R.E. Schmidt, 1998. Vascular complications associated with use of HIV protease inhibitors. Lancet, 351: 1958.
3. Bernasconi, E., A. Carota, L. Magenta, M. Pons, M. Russott and T. Moccetti, 1998. Metabolic changes in HIV-infected patients treated with protease inhibitors. AIDS., 12: 88.
4. Boufassa, F., A. Dulioust, A.S. Lascaux, L. Meyer, F. Boue, J.F. Delfraissy, A. Sobel and C. Goujard, 2001. Lipodystrophy in 685 HIV-1-treated patients: Influence of antiretroviral treatment and immunovirological response. HIV Clin. Trials, 2: 339-345.
5. Buccolo, G. and H. David, 1973. Quantitative determination of serum triglyceride by the use of enzymes. Clin. Chem., 19: 476.
6. Carr, A., K. Samaras, S. Burton, M. Law, J. Freund, D.J. Chisholm and D.A. Cooper, 1998. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS., 12: 51-58.
7. Dube, M.P., D.L. Johnson, J.S. Currier and J.M. Leedom, 1997. Protease inhibitor-associated hyperglycaemia. Lancet, 350: 713-714.
8. Eastone, J.A. and C.F. Decker, 1997. New-onset diabetes mellitus associated with use of protease inhibitor. Ann. Intl. Med., 127: 948.
9. Friedwald, W.T., R.I. Levy and D.S. Fredrickson, 1972. Estimation of concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clin. Chem., 18: 449-502.
10. Ledergerber, B., M. Egger, M. Opravil, A. Telenti and B. Hirschel et al., 1999. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet, 353: 863-868.
11. Mallal, S.A., M. John, C.B. Moore, I.R. James and E.J. McKinnon, 2000. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS., 14: 1309-1316.
12. Martinez, E., M.A. Garcia-Viejo, J.L. Blanco, L. Bianchi and E. Buira et al., 2000. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin. Infect. Dis., 31: 1266-1273.
13. Molina, J.M., G. Chene, F. Ferchal, V. Journot and I. Pellegrin et al., 1999. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS., 13: 805-810.
14. Mooser, V. and A. Carr, 2001. Antiretroviral therapy-associated hyperlipidaemia in HIV-1 disease. Curr. Opin. Lipid, 3: 313-319.
15. Moyle, G., C. Baldwin, S. Mandalia, S. Comitis, P. Burn and B. Gazzard, 2001. Changes in metabolic parameters and body shape. after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: Single-arm observational cohort. J. Acquired Immune Defic. Syndr, 28: 399-401.
16. Palella, F.J.J., K.M. Delaney, A.C. Moorman, M.O. Loveless and J. Fuhrer et al., 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Eng. J. Med., 338: 853-860.
17. Smith, C.J., I. Levy, C.A. Sabin, E. Kaya, M.A. Johnson and M.C. Lipman, 2004. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med., 5: 88-92.
18. Warnick, G.R. and J.J. Alberers, 1978. Heparin-Mn+2 quantification of high density-lipoprotein by ultrafiltration procedure for lipemic samples. Clin. Chem., 24: 900-904.